Immunovant IMVT 深 沪
等待开盘 09-30 09:30:00 美东时间
33.46
-0.030
-0.09%
华盛通- 最 高33.525
- 今 开33.43
- 成交量 121.45万股
- 最 低 32.45
- 昨 收 33.49
- 总市值 69.11亿
- 52周最高 45.42
- 市盈率 静 --
- 换手率 0.59%
- 52周最低 16.77
- 委 比 -93.52%
- 总股本 2.07亿
- 历史最高 53.75
- 量 比 0.55
- 振 幅 3.21%
- 历史最低 3.145
- 每 手 1
- 风险率 7.25%
个股概要
财务分析
公司资料
相关新闻
分红派息
- 分时图
- 日k
- 周k
- 月k
相关新闻
更多Immunovant Ends Autoimmune Skin Disorder Program
Roivant Sciences Ltd. (NASDAQ:ROIV) announced that Immunovant Inc. (NASDAQ:IMVT) plans to halt the development of IMVT-1402 as a treatment for cutaneous lupus erythematosus (CLE). The decision follows recent proof-of-concept trial results that failed to reach statistical significance. Shares of both...
09-23 21:03
Roivant And Immunovant Say Topline Results From Period 1 Of Proof-of-concept Trial of IMVT-1402 (Imeroprubart) For Cutaneous Lupus Erythematosus Did Not Achieve Statistical Significance On The Primary Endpoint
Immunovant’s proof-of-concept study of IMVT-1402 (imeroprubart) in cutaneous lupus erythematosus (CLE) did not achieve statistical significance on the primary endpoint of Cutaneous Lupus Erythematosus Disease Area and Severity Index Activity (CLASI-A) percent change from baseline at Week 12 Positive...
09-23 19:05
Roivant Announces Topline Results from Proof-of-Concept Study of IMVT-1402 in Cutaneous Lupus Erythematosus
Immunovant's IMVT-1402 failed to meet the primary endpoint in a Phase 1 CLE trial, showing no statistical significance in CLASI-A score reduction. While positive trends were observed, development in CLE will halt due to the competitive landscape. The drug demonstrated good safety, and trials in other autoimmune diseases continue.
09-23 11:00
近30亿美元，礼来买下一家刚成立的抗体公司
（来源：抗体圈） 刚刚，礼来公司宣布以最高28.75亿美元现金收购Merida Biosciences。 这家总部位于马萨诸塞州剑桥的生物技术公司，去...
09-01 16:32
财报速睇 | Immunovant 2026财年Q2营收0.00亿美元，同比增长0.0%；归母净利润亏损1.53亿美元，同比亏损扩大27.0%
华盛资讯8月6日讯，Immunovant公布2026财年Q2业绩，公司Q2营收0.00亿美元，同比增长0.0%，归母净利润亏损1.53亿美元，同比亏损扩大27.0%。
08-06 21:49
财报速睇 | Immunovant 2026财年Q2营收0.00亿美元，同比增长0.0%；归母净利润亏损1.53亿美元，同比亏损扩大26.4%
华盛资讯8月6日讯，Immunovant公布2026财年Q2业绩，公司Q2营收0.00亿美元，同比增长0.0%，归母净利润亏损1.53亿美元，同比亏损扩大26.4%。
08-06 19:47
美股大行评级 | Palantir、Snap、爵士制药获多家大行上调目标价；潜在涨幅176.34%！巴克莱维持Snap(SNAP)"超配"评级，目标价从15美元上调至16美元
今日重点评级关注：巴克莱：维持Snap"超配"评级，目标价从15美元升至16美元；Canaccord Genuity：维持阿梅雷斯克"买入"评级，目标价从59美元升至62美元
08-05 11:45
JP Morgan Maintains Overweight on Immunovant, Raises Price Target to $50
JP Morgan analyst Brian Cheng maintains Immunovant (NASDAQ:IMVT) with a Overweight and raises the price target from $47 to $50.
08-05 02:40
Insiders Cash Out at Immunovant, Helmerich & Payne, SharkNinja, PBF Energy, Venture Global
Insiders have been trading these 5 stocks: (($IMVT)), (($HP)), (($SN)), (($PBF)...
07-25 21:01
